Evaluating feasibility and efficiency of phase II adaptive platform trial designs based on the individualized screening trial of innovative glioblastoma therapy (INSIGhT)) experience Meeting Abstract


Authors: Rahman, R.; Trippa, L.; Lee, E. Q.; Arrillaga-Romany, I.; Touat, M.; Fell, G.; McCluskey, C.; Bruno, J.; Gaffey, S.; Drappatz, J.; Lassman, A.; Galanis, E.; Ahluwalia, M.; Colman, H.; Nabors, L. B.; Hepel, J.; Elinzano, H.; Schiff, D.; Chukwueke, U.; Beroukhim, R.; Batchelor, T.; Nayak, L.; McFaline-Figueroa, J. R.; Rinne, M.; Kaley, T.; Lu-Emerson, C.; Bi, W. L.; Arnaout, O.; Haas-Kogan, D.; Tanguturi, S.; Cagney, D.; Aizer, A.; Welch, M.; Doherty, L.; Lavallee, M.; Fisher-Longden, B.; Dowling, S.; Pisano, W.; Lapinskas, E.; Meredith, D.; Chiocca, E. A.; Reardon, D.; Ligon, K.; Alexander, B.; Wen, P.
Abstract Title: Evaluating feasibility and efficiency of phase II adaptive platform trial designs based on the individualized screening trial of innovative glioblastoma therapy (INSIGhT)) experience
Meeting Title: 26th Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO)
Journal Title: Neuro-Oncology
Volume: 23
Issue: Suppl. 6
Meeting Dates: 2021 Nov 18-21
Meeting Location: Boston, MA
ISSN: 1522-8517
Publisher: Oxford University Press  
Date Published: 2021-11-01
Start Page: vi68
End Page: vi69
Language: English
ACCESSION: WOS:000757356200267
PROVIDER: wos
DOI: 10.1093/neuonc/noab196.265
Notes: Meeting Abstract: CTNI-40 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Thomas Kaley
    154 Kaley